Publications

The following are a few therapeutic drug monitoring related publications, oral communications and posters from the Québec Antiretroviral Therapeutic Drug Monitoring Program team members

Publications

  • Sheehan N et collaborateurs. Ministère de la santé et des services sociaux. La pharmacométrie clinique des antirétroviraux et l’individualisation de la thérapie antirétrovirale chez les adultes et les enfants vivant avec le VIH - Guide pour les professionnels de la santé du Québec. La Direction des communications du ministère de la Santé et des Services sociaux. (full document and print-out indications tools) (link) 
  • Letarte N, Lavoie A, Sheehan N, Hurlimann T, Robb L, Lambert JP, de Denus S.  La pharmacothérapie personnalisée et la pharmacogénétique.  Pharmactuel 2013;46(4):258-68. (link)
  • Fournier C, Higgins N, Thomas R, Baril JG, Thibeault D, Lalonde R, Sheehan NL.  Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir. Ther Drug Monit 2013;35(2):264-9. (PMID: 23503454).
  • Sheehan NL, van Heeswijk RPG, Foster BC, Akhtar H, Singhal N, Séguin I, et al.  The effect of beta-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients. Molecules 2012;17:688-702. (PMID: 22241465)
  • Higgins N, Tseng A, Sheehan N, la Porte C.  Antiretroviral Therapeutic Drug Monitoring in Canada: Current Status and Recommendations for Clinical Practice. Can J Hosp Pharm 2009; 62(6): 500-9. (PMID: 22478939)
  • Sheehan NL. La pharmacocinétique clinique des antirétroviraux: de la théorie à la pratique.  Pharmactuel 2005;38(5):282-7. http://www.pharmactuel.com/sommaires/200505ve.pdf
  • Sheehan N.  Le suivi thérapeutique des antirétroviraux: théories et controverses.  Pharmactuel 2004; 37(1):21-34.  http://www.pharmactuel.com/sommaires/200401pt.pdf

Oral communications in national and international conferences

  • Sheehan NL, Lamarre V, Soudeyns H, Higgins NM, Lapointe N.  Dose adjustments of efavirenz (EFV) based on therapeutic drug monitoring (TDM) is safe and maintains virologic suppression in HIV-infected children and adolescents.  19th Annual Canadian Conference on HIV/AIDS Research.  Saskatoon, Canada, May 13-16, 2010.
  • Higgins NM, Lapointe N, Gauthier J,  Lalonde RG, Sheehan NL. Retrospective Evaluation of Efavirenz Concentrations in Pediatric Patients in an Antiretroviral Therapeutic Drug Monitoring (TDM) Program.  Abstract #8. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, USA April 7-10, 2008.
  • Higgins NM, Lalonde RG, Gibbs B, Colantonio D, Gilfix B, Boulerice A, Courchesne M, Baril JG, Blank D, Sheehan NL.  Québec Provincial Program for Antiretroviral Therapeutic Drug Monitoring.  16th Annual Canadian Conference on HIV/AIDS Research, Toronto, Canada; April 26-29, 2007.
  • Sheehan NL, Higgins NM, Boulerice A, Lalonde RG.  Evaluation of the Use of Genotypic Inhibitory Quotients in an Antiretroviral Therapeutic Drug Monitoring program [Abstract 76].  8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, April 16-18, 2007.
  • Sheehan NL, Higgins NM, Gibbs B, Colantonio D, Gilfix B, Courchesne M, Grignon B, Baril JG, Blank D, Lalonde RG. Programme québécois de pharmacométrie clinique des antirétroviraux [Abstract 131].   4e Conférence Francophone VIH/SIDA, Paris, France; March 29-31, 2007.
  • Lam S, Delisle MS, Labbé L, Smith GHR, la Porte CJL, Burger DM, Lalonde R, Sheehan NL.  Genotypic inhibitory quotient as best pharmacokinetic / pharmacodynamic predictor of virologic response to a lopinavir / saquinavir dual ritonavir boosted regimen in patients with multiresistant HIV-1 [Abstract 81]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal; April 20-22, 2006.  

Posters

  • Raiyani D, Sheehan NL, Wong AYJ, Wong D, Kovacs C, Tseng A. Fluctuations in antiretroviral concentrations during acute hepatitis C: a case report. CSHP Professional Practice Conferences, Toronto, Canada, Jan 30-Feb 3, 2016.
  • Ricard F, Wong AYJ, Lebouché B, Therrien R, Lachance MJ, Munoz M, Thibeault D, Sheehan NL. Low darunavir concentrations in patients receiving Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) and darunavir once daily [Poster 50]. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy,Washington DC, May 26-28, 2015.
  • Bilirubin as a surrogate marker for atazanavir
    plasma concentrations in a paediatric population
    Wong AYJ, Dayneka N, Brophy JC, Bowes J, la Porte CJ, Samson L. Bilirubin as a surrogate marker for atazanavir plasma concentrations in a paediatric population. 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, The Netherlands, 22-24 April 2013.
  • Sheehan NL, Baril JG, Gauthier J, Higgins NM, Therrien R, Labbe L, et al.  Determination of specific indications for antiretroviral therapeutic drug monitoring using an evidence-based approach - the Québec TDM guidelines [P_43].  13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 16-18th 2012.
  • Fournier C, Higgins N, Thomas R, Baril JG, Thibeault D, Lalonde R,  Sheehan N.  Retrospective analysis of atazanavir therapeutic drug  monitoring:  is boosting with ritonavir necessary if used with tenofovir? [Poster 41].  12th International Workshop  on Clinical Pharmacology of HIV Therapy.  Miami, USA, April 13-15 2011. 
  • Sheehan NL, Lamarre V, Soudeyns H, Higgins NM, Lapointe N.  Dose  adjustments of efavirenz based on therapeutic drug monitoring maintain virologic suppression in HIV-infected children and adolescents  [Poster 13].    11th International Workshop on Clinical Pharmacology of  HIV Therapy, Sorrento, Italy, April 7-9, 2010.
  • Sheehan NL, la Porte C, Slayter K, Zhang G, Lalonde RG, Haase D, van Heeswijk RPG, Labbé L.  The Effects of Aging on the Pharmacokinetics of Nelfinavir and M8 in HIV-1-Infected Individuals. [Poster 52].   10thInternational Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, the Netherlands, April 15 to 17, 2009.
  • Gauthier J, Boucher M, Higgins N, Moreau J, Yang H, Sheehan NL. Therapeutic drug monitoring of lopinavir/ritonavir (tablet formulation) in pregnancy [Poster 49].  10th International Workhop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, April 15-17 2009.
  • Tang I, Orng B, Benyayer G, Fortier S, Perreault S, Labbé L, Higgins NM, Lalonde RG, Sheehan NL.  Evaluation of physician satisfaction with the Québec provincial antiretroviral therapeutic drug monitoring program [Poster 55].  9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, USA, April 7 - 9, 2008.
  • Orng B, Fortier S, Benyayer G, Tang I, Labbé L, Perreault S, Higgins NM, Lalonde RG, Sheehan NL.  Physician adherence to the pharmacological advice in an antiretroviral therapeutic drug monitoring program [Poster 56].   9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, USA, April 7 - 9, 2008.
  • Sheehan NL, Higgins NM, Boulerice A, Lalonde RG.  Evaluation of the Use of Genotypic Inhibitory Quotients in an Antiretroviral Therapeutic Drug Monitoring program [Poster 76].  8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, April 16-18, 2007.
  • Lam S, Delisle MS, Labbé L, Smith GHR, la Porte CJL, Burger DM, Lalonde R, Sheehan NL.  Genotypic inhibitory quotient as best pharmacokinetic / pharmacodynamic predictor of virologic response to a lopinavir / saquinavir dual ritonavir boosted regimen in patients with multiresistant HIV-1 [Poster 81]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal; April 20-22, 2006. 
  • Sheehan NL, Bourbeau M, Foster BC, Séguin I, Akhtar H, Singhal N, Boulassel MR, DelBalso LD, Lalonde RG, van Heeswijk R, Cameron DW.  The effect of beta-carotene on the steady-state pharmacokinetics of nelfinavir and its M8 metabolite [Poster 2.20].  6th International Workshop on Clinical Pharmacology of HIV Therapy, Québec City, Canada; April 28-30, 2005.